ArticleAsian Pacific journal of cancer prevention : APJCP2025
High APEX1 Expression Facilitates Osteosarcoma Cell Proliferation.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a serious malignancy affecting children and young adults; however, there is limited improvement in the survival of patients with OS over the past four decades. Molecular targeted therapy is a promising treatment strategy for OS. Apurinic/apyrimidinic exonuclease 1 (APEX1)-a key factor for DNA damage repair-is associated with OS proliferation, but the underlying molecular mechanism remains unclear. APEX1 expression in OS tissues and paired paracancerous tissues and in human osteoblast cell line hFOB1.19 and OS cell lines was determined using real-time quantitative PCR (RT-qPCR). APEX1-shRNA and NC-shRNA lentiviral vectors were constructed and transfected into MG-63 cells. The effects of APEX1 knockdown on MG-63 cell proliferation and apoptosis were assessed using MTT, xenograft tumor growth, and terminal deoxynucleotidyl transferase dUTP nick end labeling assays. Expression changes of apoptosis- and angiogenesis-related genes due to APEX1 knockdown were detected using RT-qPCR and immunohistochemistry. To preliminarily determine the mechanism by which APEX1 affects OS cell proliferation, transcription factors were predicted using three databases, and construction of protein-protein interaction network, gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed. APEX1 expression was higher in OS tissues than in paracancerous tissues. APEX1 expression was also higher in OS cell lines than in hFOB1.19 cells, with the highest APEX1 expression observed in MG-63 cells. APEX1 knockdown mediated by APEX1-shRNA lentivirus markedly suppressed MG-63 cell proliferation both in vitro and in vivo and induced their apoptosis. APEX1 knockdown downregulated CD31 expression but had no effect on the expression of P53 and Caspase3. Bioinformatics analyses suggested that USF1 or SP1 regulates APEX1 transcription and its recruitment in DNA damage response pathways, affecting OS cell proliferation. Thus, high APEX1 expression in OS facilitates cell proliferation likely via CD31, and USF1 or SP1 may regulate APEX1 transcription and its recruitment in DNA damage response pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.